Our grant program has broad reach, drawing proposals from the most talented scientists across the country. A vigorous peer review process ensures that the proposals we accept are of the highest quality. This foundation of excellence leads to exceptional projects yielding results that make a difference in the lives of people with arthritis.
Study Could Revolutionize Treatment for Osteoarthritis
The Arthritis Foundation awarded a $1 million, multi-institutional grant that could revolutionize future treatment for osteoarthritis (OA) and ignite a new era in drug discovery, as part of our research strategic goal to develop new interventions for OA. By studying anterior cruciate ligament (ACL) tears in the knee, a major risk factor for developing osteoarthritis, researchers seek to discover tools and treatments to detect and reverse OA before symptoms ever appear. Read more about this study.
Developing Best Standard Treatments for JA
Ask 10 pediatric rheumatologists how to treat a child with arthritis and very likely you’ll get 10 different treatment strategies. However, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) is looking to change that by developing consensus treatment plans for a number childhood rheumatic diseases. Read about the consensus process and overviews of the resulting treatment plans.
Rheumatoid Arthritis Responder Challenge
Crowdsourcing, the practice of obtaining needed services, ideas, or content by soliciting contributions from a large group of people, is a relatively new approach to solving problem. Read about this innovative Challenge to improve the treatment of rheumatoid arthritis and the Arthritis Foundation's role in bringing it to the people.
Arthritis Foundation Joins Accelerated Medicines Partnership
The Arthritis Foundation is part of an exciting new initiative, the Accelerating Medicines Partnership (AMP). AMP is a new venture that brings together the Foundation for the National Institutes of Health (FNIH), the National Institute of Health (NIH), 10 bio pharmaceutical companies and several non-profit organizations to work toward a common goal of earlier drug discovery and development for diseases, including rheumatoid arthritis and lupus. Read more about this initiative.